title: NCCN endorses PSA testing in absence of better alternatives.
authors.forename: Thomas
authors.initials: T
authors.lastname: Reinke
mesh_terms: D026683:Advisory Committees; D000368:Aged; D001706:Biopsy; D055088:Early Detection of Cancer; D019317:Evidence-Based Medicine; D005189:False Positive Reactions; D006801:Humans; D019458:Insurance Coverage / Q000191:economics*; D007348:Insurance, Health / Q000191:economics*; D008297:Male; D006278:Medicare / Q000191:economics; D008875:Middle Aged; D058991:Patient Protection and Affordable Care Act / Q000191:economics; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood*; D012955:Societies, Medical; D014481:United States
chemical_list: D017430:Prostate-Specific Antigen